Links
Organizations
Conferences
Info & Opinion
- Applied Clinical Trials
- Bio-IT World
- ClinPsych
- Clinical Trials Today
- Tom Lamb
- George Laszlo
- Pharma Voice
- Ed Silverman
- TJOLS
January 8, 2009
Speeding Myozyme To Market
Genzyme Uses Adaptive Design
In addition to embarking on a rapid adoption of an adaptive design, the biotech company is making an unusually swift and public acknowlegment of an innovative strategy.
- Home
- Tag
- pompe
We’ve heard a few presentations from Genzyme about Pompe disease, a rare respiratory and musculatory disorder afflicting one in 40 to 300,000 people. (It’s an “orphan” condition, and Genzyme’s intravenous drug, Myozyme, was approved for Pompe disease in infants in…
No articles available
